European approval granted for Pexion® - innovative treatment for canine epilepsy discovered by BioCrea, developed and launched by Boehringer Ingelheim
(Thomson Reuters ONE) -
BioCrea /
European approval granted for Pexion® - innovative treatment for canine epilepsy
discovered by BioCrea, developed and launched by Boehringer Ingelheim
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Radebeul, Germany, May 06, 2013 - BioCrea GmbH (BioCrea), the first-in-class CNS
drug discovery specialists validated through pharma partnerships, announced that
Pexion® (Imepitoin) has been recommended for marketing authorisation by the
Committee for Medicinal Products for Veterinary Use (CVMP) of the European
Medicines Agency (EMA). Imepitoin was discovered by Dr Tom Kronbach, Chief
Executive Officer at BioCrea, and his team in 1995. Following a 2004 in-
licensing agreement, Pexion® was further developed and launched by Boehringer
Ingelheim.
In December 2012, the CVMP adopted a positive opinion to recommend the granting
of a marketing authorisation for the veterinary medicinal product Pexion® 100mg
and 400mg tablets, intended for the reduction of the frequency of generalised
seizures due to idiopathic epilepsy in dogs.
Imepitoin is a centrally acting anti-epileptic substance, which inhibits
seizures via potentiation of GABAA receptor-mediated inhibitory effects on the
neurons. In addition, Imepitoin has a weak calcium channel blocking effect.
Pexion® has been launched by Boehringer Ingelheim in Europe in April 2013.
"This recommendation by the CVMP is excellent news for our partner Boehringer
Ingelheim and for dog owners, whose pets suffer epilepsy," said Dr Tom Kronbach,
Chief Executive Officer of BioCrea GmbH. "Fundamentally, CVMP concluded that
Pexion® has a favourable efficacy profile and demonstrated a superior safety
profile compared to current standard treatments[1]. Moreover, this
recommendation is proof that our discovery engine and approach defines small
molecule drugs that do reach the market."
"Until now, the two most common treatments were sedatives that have been in use
for more than 100 years", said Dr Joachim Hasenmaier, responsible for the
Corporate Board Divisions Animal Health and Consumer Healthcare at Boehringer
Ingelheim. "Therefore, we are very proud to provide a real innovation in this
therapeutic area that significantly improves upon the current standard
treatment."
About BioCrea
BioCrea is the Radebeul-based first-in-class drug discovery specialist validated
through pharma partnerships. The company boasts a provable track record in
effective drug discovery driven by knowledge, flexibility and extensive
experience. BioCrea's expertise is founded on the continuing discovery and
optimization of selective ion channel and enzyme modulators - agents that offer
significant potential for maximizing the efficacy and tolerability of new
therapeutics. BioCrea was awarded Top Innovator status of the "Top 100" Most
Innovative Companies in Germany, 2012 by compamedia GmbH.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical
companies. Headquartered in Ingelheim, Germany, it operates globally with 140
affiliates and more than 46,000 employees. Since it was founded in 1885, the
family-owned company has been committed to researching, developing,
manufacturing and marketing novel medications of high therapeutic value for
human and veterinary medicine.
Contact
Dr. Tom Kronbach
CEO, BioCrea GmbH
Tel.: +49 351 / 4043 3332
Fax: +49 351 / 4043 3216
tom.kronbach(at)biocrea.com
-----------------------------------------
[1] European Public Assessment Report (EPAR): Pexion (Imepitoin). London:
European Medicines Agency; 2013. Available at: www.ema.europe.eu.
Press Release PDF:
http://hugin.info/156612/R/1699368/560527.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: BioCrea via Thomson Reuters ONE
[HUG#1699368]
Unternehmensinformation / Kurzprofil:
Datum: 06.05.2013 - 09:00 Uhr
Sprache: Deutsch
News-ID 256247
Anzahl Zeichen: 4902
contact information:
Town:
Radebeul
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 339 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"European approval granted for Pexion® - innovative treatment for canine epilepsy discovered by BioCrea, developed and launched by Boehringer Ingelheim"
steht unter der journalistisch-redaktionellen Verantwortung von
BioCrea (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
